Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeut... Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. Mehr anzeigen
Halozyme to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO, Nov. 27, 2024 SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today...
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions PR Newswire SAN DIEGO, Nov. 22, 2024 SAN DIEGO, Nov. 22, 2024 /PRNewswire/ -- Halozyme...
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction PR Newswire SAN DIEGO, Nov. 14, 2024 Combination Would Create a Global Innovative Services...
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS PR Newswire SAN DIEGO, Oct. 31, 2024 Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to...
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE PR Newswire SAN DIEGO, Oct. 24, 2024 Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX...
Halozyme to Report Third Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO, Oct. 23, 2024 SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.4393 | 3.06038698703 | 47.03 | 48.4693 | 46.26 | 1829340 | 47.13561749 | CS |
| 4 | 0.1693 | 0.350517598344 | 48.3 | 49.79 | 46.26 | 1346243 | 47.79526822 | CS |
| 12 | -12.0907 | -19.9648282695 | 60.56 | 62.128 | 42.01 | 1754795 | 50.16164172 | CS |
| 26 | -3.7807 | -7.23578947368 | 52.25 | 65.5327 | 42.01 | 1510579 | 53.46876619 | CS |
| 52 | 11.1893 | 30.0142167382 | 37.28 | 65.5327 | 33.15 | 1377126 | 47.71281092 | CS |
| 156 | 8.0693 | 19.9735148515 | 40.4 | 65.5327 | 29.85 | 1230698 | 44.10013879 | CS |
| 260 | 30.2293 | 165.730811404 | 18.24 | 65.5327 | 12.71 | 1246836 | 39.5170614 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
